Welcome to our dedicated page for Matinas Biopharm news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas Biopharm stock.
Matinas Biopharma (MTNB) is a clinical-stage biopharmaceutical innovator leveraging lipid-crystal nanoparticle technology to develop oral anti-infectives for complex diseases. This page aggregates all official news releases and verified updates related to the company’s clinical progress, strategic partnerships, and regulatory milestones.
Investors and industry professionals will find timely updates on clinical trial results, FDA communications, and corporate developments, including advancements in MTNB’s encochleated drug pipeline. The resource prioritizes accuracy and relevance, offering stakeholders a streamlined way to track the company’s work in transforming anti-infective therapies through nanotechnology.
Key content categories include updates on lead candidates like MAT2203 (oral amphotericin B) and MAT2501 (encochleated amikacin), intellectual property announcements, and collaborations addressing orphan infectious diseases. All materials are sourced directly from company filings and authorized communications to ensure reliability.
Bookmark this page for efficient access to MTNB’s latest developments in drug reformulation and nano-encapsulation technology. Check back regularly for critical updates that could inform long-term investment and research strategies in the biopharmaceutical sector.
Matinas BioPharma (MTNB) announced significant clinical results for MAT2203, an oral formulation of amphotericin B, at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). Dr. Marisa H. Miceli presented a compassionate use case where MAT2203 effectively treated a patient with a rare, resistant fungal infection (Rhodotorula mucilaginosa) after traditional IV treatment led to severe kidney toxicity. The patient showed substantial clinical improvement, tolerated MAT2203 well over six months, and completed therapy with no renal adverse effects. This success highlights MAT2203's potential as a safer, outpatient alternative for patients requiring long-term antifungal treatment. Matinas is preparing for Phase 3 trials with the FDA to further evaluate MAT2203's efficacy for invasive fungal infections, though it remains unapproved globally.
Matinas BioPharma (MTNB) reported 2022 financial results, posting $3.2 million in revenue, a substantial increase from $33,000 in 2021, attributed to its collaboration with BioNTech. Total costs rose to $27.8 million, reflecting advancements in clinical development. The company's net loss decreased to $21.0 million from $23.7 million year-over-year. Key milestones ahead include FDA meetings regarding MAT2203 for invasive fungal infections and potential non-dilutive funding from BARDA or NIH. Promising data from ongoing collaborations with BioNTech and National Resilience are expected in 2023, enhancing the application of their lipid nanocrystal platform.
Matinas BioPharma Holdings, Inc. (MTNB) will report its 2022 financial results on March 15, 2023, after market close. A conference call hosted by management will occur at 4:30 p.m. ET to discuss the results and provide a business update. The company focuses on innovative intracellular delivery of nucleic acids and small molecules via its lipid nanocrystal (LNC) platform, aimed at enhancing patient access and clinical impact. Matinas is developing its internal product portfolio and collaborating with pharmaceutical companies to leverage its LNC technology, which shows potential in overcoming current delivery challenges in therapies such as mRNA and vaccines.
Matinas BioPharma (NYSE American: MTNB) has announced that its oral formulation of amphotericin B, MAT2203, will be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) on April 18, 2023. The company is developing MAT2203 for treating invasive fungal infections with a focus on reducing toxicity associated with traditional intravenous amphotericin B. Presentations will cover a Phase II trial for cryptococcal meningitis and a case of osteomyelitis treatment. Matinas aims to leverage its lipid nanocrystal technology for broader applications, improving patient access and clinical outcomes.
Matinas BioPharma (MTNB) reported a successful 2022, validating its lipid nanocrystal (LNC) platform for delivering therapies, particularly MAT2203 for fungal infections. The company has partnerships with BioNTech and National Resilience, aiming for initial in vivo data by mid-2023. With approximately $28.8 million in cash, Matinas expects to fund operations through Q2 2024. The firm plans to engage with BARDA and the FDA regarding MAT2203's Phase 3 study. Key developments include a focus on nucleic acids and the potential for expanding internal product pipelines.
Matinas BioPharma (NYSE AMER: MTNB) will hold a conference call on January 30, 2023, at 4:30 p.m. ET to discuss its business outlook for 2023 and provide corporate updates. The call will cover details about ongoing programs and third-party collaborations. Interested participants can join via telephone or through a live webcast on the company's website, where the presentation will be archived for 90 days. Matinas focuses on enhancing intracellular delivery of nucleic acids and small molecules using its innovative lipid nanocrystal (LNC) technology, aiming to tackle challenges in drug delivery.
Matinas BioPharma (MTNB) announced a strategic collaboration with National Resilience, Inc., focusing on the oral delivery of nucleic acids using Matinas' lipid nanocrystal (LNC) platform. This agreement includes a comprehensive research program for designing, formulating, and testing nucleic acid formats. The LNC technology may enhance intracellular drug delivery, offering advantages over traditional methods with no observed immunogenicity or cytotoxicity. CEO Jerome D. Jabbour expressed excitement about the collaboration, emphasizing its distinct nature from ongoing projects with BioNTech.
Matinas BioPharma Holdings, Inc. (MTNB) announced significant progress in its Phase 2 EnACT study for MAT2203, achieving a remarkable 95% two-week survival rate in cryptococcal meningitis patients. The treatment surpassed primary endpoint thresholds, showing a 90% overall survival rate through 18 weeks. The pivotal Phase 3 trial is set to commence in Q1 2023, backed by the NIH. Financially, the company reported $33.1 million in cash, sufficient for operations through 2023, with a reduced net loss of $5.5 million for Q3 2022.
Matinas BioPharma Holdings (MTNB) announced a conference call on November 2, 2022, at 4:30 PM ET to discuss third-quarter financial results for the period ending September 31, 2022. The company specializes in intracellular delivery technologies for nucleic acids and small molecules via its lipid nanocrystal (LNC) platform. Their innovative approach aims to enhance drug delivery efficiency, positioning Matinas for future collaborations and product developments.
Matinas BioPharma Holdings announced positive interim results for MAT2203, an oral formulation of amphotericin B, from its Phase 2 EnACT trial for cryptococcal meningitis treatment. Notably, the two-week survival rate in Cohort 4 reached 95% among 40 patients, exceeding the primary endpoint for CSF yeast clearance. MAT2203 demonstrated favorable safety, showing no kidney toxicity over six weeks of treatment. A pivotal Phase 3 trial is set to begin in Q1 2023, aimed at further validating MAT2203's efficacy.
FAQ
What is the current stock price of Matinas Biopharm (MTNB)?
What is the market cap of Matinas Biopharm (MTNB)?
